Clinical Trial Update: Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of BMS-582664 with FOLFIRI or FOLFOX for gastrointestinal neoplasms has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasms

Drugs mentioned

• BMS-582664
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Gastrointestinal Neoplasms | Phase 1 | Status: TERMINATED